Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

K. Rockstroh, Jürgen; Lacombe, Karine; M. Viani, Rolando; Orkin, Chloe; Wyles, David; F. Luetkemeyer, Anne; Soto-Malave, Ruth; Flisiak, Robert; Bhagani, Sanjay; E. Sherman, Kenneth; Shimonova, Tatiana; Ruane, Peter; Sasadeusz, Joseph; Slim, Jihad; Zhang, Zhenzhen; Samanta, Suvajit; I. Ng, Teresa; Gulati, Abhishek; P. Kosloski, Matthew; S. Shulman, Nancy; Trinh, Roger; Sulkowski, Mark

doi:10.1093/cid/ciy220

Public

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study

Published in Clinical Infectious Diseases • Mar 13, 2018

Authors:

Jürgen K. Rockstroh

Karine Lacombe

Rolando M. Viani

Abstract

Background: Once-daily glecaprevir coformulated with pibrentasvir (glecaprevir/pibrentasvir) demonstrated high rates of sustained virologic response 12 weeks after treatment (SVR12) in patients with hepatitis C virus (HCV) genotype 1-6 infection. This phase 3 study evaluated the efficacy and safety ...

Subject

Internal medicine

Coinfection

Hepatitis C virus

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!